The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Osimertinib + ipilimumab in EGFR-mutated NSCLC
Sonam Puri, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, discusses an going Phase Ib trial which explores the combination of osimertinib, an EGFR tyrosine kinase inhibitor (TKI) with ipilimumab, a monoclonal antibody drug in patients with EGFR mutant non-small cell lung cancer as first line treatment. Data from a past study which looked older generation TKIs combined with ipilimumab showed tremendous improvement for patients in progression-free survival (PFS) and overall survival, but this study was halted due to GI toxicities in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
